110 related articles for article (PubMed ID: 38651414)
1. Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer.
Hendrixson M; Gladkiy Y; Thyagarajan A; Sahu RP
Med Sci (Basel); 2024 Apr; 12(2):. PubMed ID: 38651414
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
4. Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Wang HL; Ma X; Guan XY; Song C; Li GB; Yu YM; Yang LL
Pharmacol Res; 2022 Mar; 177():106050. PubMed ID: 34973468
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Wang WL; Tang ZH; Xie TT; Xiao BK; Zhang XY; Guo DH; Wang DX; Pei F; Si HY; Zhu M
Asian Pac J Cancer Prev; 2014; 15(14):5691-6. PubMed ID: 25081687
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in non-small cell lung cancer.
Zhang J; Gold KA; Kim E
Expert Opin Investig Drugs; 2012 Sep; 21(9):1417-26. PubMed ID: 22725255
[TBL] [Abstract][Full Text] [Related]
7. MiR-600 mediates EZH2/RUNX3 signal axis to modulate breast cancer cell viability and sorafenib sensitivity.
Zhao Q; Li D; Feng J; Jinsihan D
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23613. PubMed ID: 38229326
[TBL] [Abstract][Full Text] [Related]
8. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Zhao J; Lin E; Bai Z; Jia Y; Wang B; Dai Y; Zhuo W; Zeng G; Liu X; Cai C; Li P; Zou B; Li J
BMC Cancer; 2023 Dec; 23(1):1198. PubMed ID: 38057830
[TBL] [Abstract][Full Text] [Related]
10. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of sorafenib resistance associated with ferroptosis in HCC.
Guo L; Hu C; Yao M; Han G
Front Pharmacol; 2023; 14():1207496. PubMed ID: 37351514
[TBL] [Abstract][Full Text] [Related]
12. Lipid Nanocarrier-Based Drug Delivery Systems: Therapeutic Advances in the Treatment of Lung Cancer.
Kim SJ; Puranik N; Yadav D; Jin JO; Lee PCW
Int J Nanomedicine; 2023; 18():2659-2676. PubMed ID: 37223276
[TBL] [Abstract][Full Text] [Related]
13. Emerging evidence and treatment paradigm of non-small cell lung cancer.
Liu SM; Zheng MM; Pan Y; Liu SY; Li Y; Wu YL
J Hematol Oncol; 2023 Apr; 16(1):40. PubMed ID: 37069698
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
